找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Cancer Therapy; Monoclonal Antibodie Hans G. Beger (Professor of Surgery),Markus Büchle Conference proceedings 1989 Springer-Verlag Berlin

[復制鏈接]
查看: 17734|回復: 54
樓主
發(fā)表于 2025-3-21 17:19:26 | 只看該作者 |倒序瀏覽 |閱讀模式
書目名稱Cancer Therapy
副標題Monoclonal Antibodie
編輯Hans G. Beger (Professor of Surgery),Markus Büchle
視頻videohttp://file.papertrans.cn/222/221213/221213.mp4
圖書封面Titlebook: Cancer Therapy; Monoclonal Antibodie Hans G. Beger (Professor of Surgery),Markus Büchle Conference proceedings 1989 Springer-Verlag Berlin
描述A variety of new cancer therapy modalities are discussed and evaluated in this book. It aims to demonstrate that the combination of classical chemo- and radiotherapy with new approaches in the field of immunotherapy can result in an improved treatment modality. Immunotherapy in this context consists of therapy with monoclonal antibodies, hematopoietic growth factors and other lymphokines. Results of early clinical trials with IL-2, GM-CSF and monoclonal antibodies against gastrointestinal tumors and melanoma are included. The progress in regional chemotherapy strategies, for example of the liver, is shown. In addition, the development of new chemotherapeutic agents with a different mode of action as well as better tolerability is presented. The use of hormones, such as LH-RH agonists, allows hormone-dependent tumors such as prostatic and breast cancer to be treated without strong adverse reactions. These recent findings give the reader insight into exciting therapeutic directions made possible by such combined, rather than single, modalities.
出版日期Conference proceedings 1989
關鍵詞breast cancer; cancer; cancer therapy; chemotherapy; clinical trial; hormones; immunotherapy; liver; melanom
版次1
doihttps://doi.org/10.1007/978-3-642-73721-3
isbn_softcover978-3-642-73723-7
isbn_ebook978-3-642-73721-3
copyrightSpringer-Verlag Berlin Heidelberg 1989
The information of publication is updating

書目名稱Cancer Therapy影響因子(影響力)




書目名稱Cancer Therapy影響因子(影響力)學科排名




書目名稱Cancer Therapy網絡公開度




書目名稱Cancer Therapy網絡公開度學科排名




書目名稱Cancer Therapy被引頻次




書目名稱Cancer Therapy被引頻次學科排名




書目名稱Cancer Therapy年度引用




書目名稱Cancer Therapy年度引用學科排名




書目名稱Cancer Therapy讀者反饋




書目名稱Cancer Therapy讀者反饋學科排名




單選投票, 共有 1 人參與投票
 

0票 0.00%

Perfect with Aesthetics

 

1票 100.00%

Better Implies Difficulty

 

0票 0.00%

Good and Satisfactory

 

0票 0.00%

Adverse Performance

 

0票 0.00%

Disdainful Garbage

您所在的用戶組沒有投票權限
沙發(fā)
發(fā)表于 2025-3-21 22:17:20 | 只看該作者
板凳
發(fā)表于 2025-3-22 02:13:26 | 只看該作者
https://doi.org/10.1007/978-981-19-5570-9lonal antibodies has rapidly led to clinical investigations. Experience with monoclonal antibodies in the treatment of patients with melanoma is limited [4, 9, 10, 12, 13, 17, 19] because only small groups of patients have been treated so far. According to these studies, treatment with ganglioside antibodies appears most promising.
地板
發(fā)表于 2025-3-22 05:04:32 | 只看該作者
5#
發(fā)表于 2025-3-22 11:03:17 | 只看該作者
6#
發(fā)表于 2025-3-22 16:41:33 | 只看該作者
Mab 17-1A Used for Therapy of Patients with Metastatic Colorectal Carcinomasially on fetal cells. On normal mature cells, TAA might be detected only by highly sensitive techniques or after manipulation of the cell membrane. On malignant cells, TAA are often re-expressed in high concentrations. Such antigens can be exploited not only for diagnostic purposes, but also as targets for immunotherapy.
7#
發(fā)表于 2025-3-22 17:07:38 | 只看該作者
Immunotherapy of Malignant Melanomaslonal antibodies has rapidly led to clinical investigations. Experience with monoclonal antibodies in the treatment of patients with melanoma is limited [4, 9, 10, 12, 13, 17, 19] because only small groups of patients have been treated so far. According to these studies, treatment with ganglioside antibodies appears most promising.
8#
發(fā)表于 2025-3-22 21:34:30 | 只看該作者
The Role of Interferon in the Management of Patients with Hairy Cell Leukemia and Multiple Myeloma of cancer, particularly since in 1981 highly purified material produced by recombinant DNA technology has become available in addition to natural IFNs [25, 51, 59]. So far, the most impressive clinical results have been achieved in hematologic disorders, especially in hairy cell leukemia [26, 41, 54].
9#
發(fā)表于 2025-3-23 02:08:21 | 只看該作者
10#
發(fā)表于 2025-3-23 06:47:33 | 只看該作者
 關于派博傳思  派博傳思旗下網站  友情鏈接
派博傳思介紹 公司地理位置 論文服務流程 影響因子官網 吾愛論文網 大講堂 北京大學 Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點評 投稿經驗總結 SCIENCEGARD IMPACTFACTOR 派博系數 清華大學 Yale Uni. Stanford Uni.
QQ|Archiver|手機版|小黑屋| 派博傳思國際 ( 京公網安備110108008328) GMT+8, 2025-10-7 08:56
Copyright © 2001-2015 派博傳思   京公網安備110108008328 版權所有 All rights reserved
快速回復 返回頂部 返回列表
灯塔市| 大厂| 平乡县| 墨玉县| 奇台县| 瑞丽市| 六枝特区| 乐至县| 子长县| 专栏| 山阴县| 辉县市| 定安县| 慈溪市| 卫辉市| 江都市| 丽水市| 肇庆市| 昭苏县| 凤冈县| 抚远县| 防城港市| 平陆县| 舒兰市| 湘西| 石阡县| 永新县| 神农架林区| 五寨县| 黔西县| 馆陶县| 德格县| 昭平县| 大厂| 阿尔山市| 乌海市| 南平市| 察隅县| 镇安县| 嘉定区| 华坪县|